Pharmacological Management of Cardiorenal Syndromes by House, Andrew A. et al.
SAGE-Hindawi Access to Research
International Journal of Nephrology
Volume 2011, Article ID 630809, 8 pages
doi:10.4061/2011/630809
Review Article
Pharmacological Management of Cardiorenal Syndromes
Andrew A. House,1,2 Mikko Haapio,3 Johan Lassus,4 Rinaldo Bellomo,5
andClaudioRonco6
1Division of Nephrology, London Health Sciences Centre, University Hospital, 339 Windermere Road,
London, ON, Canada N6A 5A5
2Division of Nephrology, Schulich School of Medicine and Dentistry, University of Western Ontario,
Londond, ON, Canada N6A 3K7
3Division of Nephrology, HUCH Meilahti Hospital, P.O. Box 340, Helsinki FI-00029, Finland
4Division of Cardiology, HUCH Meilahti Hospital, P.O. Box 340, Helsinki FI-00029, Finland
5Department of Intensive Care, Austin Hospital, Melbourne VIC 3084, Australia
6Department of Nephrology, San Bortolo Hospital, International Renal Research Institute Vicenza (IRRIV), Viale Rodolﬁ 37,
Vicenza 36100, Italy
Correspondence should be addressed to Andrew A. House, andrew.house@lhsc.on.ca
Received 10 August 2010; Accepted 28 March 2011
Academic Editor: Anjay Rastogi
Copyright © 2011 Andrew A. House et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Cardiorenal syndromes are disorders of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce
acute or chronic dysfunction of the other. The pharmacological management of Cardiorenal syndromes may be complicated
by unanticipated or unintended eﬀects of agents targeting one organ on the other. Hence, a thorough understanding of the
pathophysiology of these disorders is paramount. The treatment of cardiovascular diseases and risk factors may aﬀect renal
function and modify the progression of renal injury. Likewise, management of renal disease and associated complications can
inﬂuence heart function or inﬂuence cardiovascular risk. In this paper, an overview of pharmacological management of acute and
chronic Cardiorenal Syndromes is presented, and the need for high-quality future studies in this ﬁeld is highlighted.
1.Introduction
Cardiorenalsyndromes(CRS)aﬀectabroadarrayofpatients
in both acute and chronic clinical situations, with signif-
icant ramiﬁcations in terms of morbidity and mortality.
For instance, type 1 CRS, as seen in patients experienc-
ing an abrupt increase in serum creatinine >0.3mg/dL
(>26μmol/L) during hospitalization for acute decompen-
sated heart failure (ADHF), is associated with increased
length of stay, more complications, and higher mortality.
In chronic heart failure, the coexistence of chronic kid-
ney disease (CKD) with glomerular ﬁltration rate (GFR)
<60mL/min/1.73m2 (type 2 CRS) signiﬁcantly increases
the risk for mortality. Acute kidney injury, for example,
following contrast for radiological imaging, has been associ-
atedwithsubsequentadversecardiovascularevents,so-called
type 3 CRS. Numerous studies have identiﬁed CKD as a
graded and independent risk factor for cardiovascular events
and outcomes, representing type 4 CRS. Systemic disorders
that involve both the heart and kidneys (type 5 CRS) are
a heterogeneous group, but when examining sepsis as an
example,increasingnumbersoforgansinvolveddramatically
increases mortality, particularly in those with evidence of
septic cardiomyopathy [1] and acute kidney injury [2].
In this paper, we review brieﬂy the pharmacological
managementofthevarioussubtypesofCRS,highlightingthe
needforhigh-qualityfuturestudies.Table 1 presentsapoint-
form summary of suggested management for these subtypes,
along with pitfalls and questions for future research.
2. Management of Acute Cardiorenal
Syndrome (Type 1)
Type 1 CRS appears in the setting of ADHF or cardio-
genic shock for a number of reasons, with hemodynamic2 International Journal of Nephrology
Table 1
CRS subtype General considerations and recommended therapies Caveats/areas for future investigation
Acute cardio-renal (CRS 1)
Reduce congestion with diuretics, balance negative
ﬂuid balance with intravascular reﬁlling Infusion versus bolus; dose; electrolyte concerns
Renin-angiotensin blockade may need to be reduced
or even withheld with worsening renal function
With preserved or elevated blood pressure, empiric
use of vasodilators
Limited data from uncontrolled trials;
nitroprusside limited by toxicity
Nesiritide may improve cardiac output and cause
signiﬁcant diuresis
Conﬂicting results of clinical trials; ongoing trials
to determine safety, eﬃcacy, and dose
With low pressure, poor cardiac output, inotropes
may be required as a bridge to recovery or
transplantation
Intropes may provoke ischemia or arrhythmia;
increased mortality in some studies; mechanical
support (balloon pump, ventricular assist device,
etc.) may be required
Chronic cardio-renal (CRS 2)
Renin-angiotensin blockade is of primary
importance; may need to be reduced or withheld
with signiﬁcantly worsening renal function
Most studies have excluded patients with
signiﬁcant kidney disease; increase in creatinine
>30% or potassium >5.0mmol/L cause for concern
Aldosterone antagonists may be cautiously
considered
Creatinine >2.5mg/dL (>220μmol/L) or
potassium >5.0mmol/L were exclusions in clinical
trials
Beta-blockers are important adjuncts in congestive
heart failure and/or ischemic heart disease
Some agents (atenolol, nadolol, sotalol) have
altered pharmacokinetics; carvedilol may have an
advantage over older drugs
Concomitant anemia may worsen symptoms and
outcomes
Unclear role of erythropoiesis-stimulating agents;
parenteral iron encouraging in terms of symptoms
as well as improved renal function
A c u t er e n o - c a r d i a c( C R S3 )
Contrast nephropathy is a common example of CRS
3; prevention is likely the best strategy
Numerous strategies tested; isotonic ﬂuids and
possibly N-acetylcysteine have the best evidence to
date
Preexisting chronic kidney disease, age, diabetes,
and volume contraction are amongst risks that
predispose to contrast nephropathy
Low osmolar, nonionic contrast may reduce risk of
CRS 3
Chronic reno-cardiac (CRS 4)
Multifaceted disorder with both traditional and
non-traditional risk factors; graded risk based on
degree of chronic kidney disease
Lifestyle modiﬁcation (smoking, weight control,
activity, and nutrition) of probable beneﬁt but
limited evidence
Anemia closely related to poor outcomes; current
guidelines recommend starting for sustained
hemoglobin <10g/dL (100g/L) and targeting
10–12g/dL (100–120g/L)
Studies showed increased harm from higher
targets; concerns have been raised about stroke
risk, and risk in patients with cancer
Management of chronic kidney disease-related
mineral and bone disorders; phosphate binders,
vitamin D analogs, controlling PTH
As yet, eﬃcacy largely limited to putative surrogate
endpoints; ongoing trials with hard cardiovascular
endpoints awaited
Lipid lowering with statins
Eﬃcacy in dialysis-dependent patients is
questioned; in lesser degrees of chronic kidney
disease risk reduction is clearly established
Secondary cardio-renal (CRS 5)
Sepsis is a common example of CRS 5; management
needs to focus on protecting/optimizing both
cardiac and renal function
Other secondary causes of CRS 5 are a fruitful area
for ongoing research
Volume and pressor support to achieve a mean
arterial pressure ≥65mmHg and central venous
pressure of 8 to 12mmHg and adequate oxygen
delivery
Early protocol-driven interventions lower risk of
adverse renal outcomes and death due to
cardiovascular collapse
Norepinephrine preferred over dopamine in a
randomized controlled trial (most patients had
septic shock)
Higher incidence of cardiac arrhythmia and trend
to increased need for dialysis with dopamine
Addition of low-dose vasopressin in select patients May decrease risk of adverse cardiac and renal
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derangements ranging from acute pulmonary edema with
hypertension through severe peripheral ﬂuid overload to
cardiogenicshockandhypotension[3–5].Unfortunately,the
management of type 1 CRS is largely empiric, as many of
thetraditionaltherapiestorelievecongestiveand/orischemic
symptoms (diuretics, vasodilators, and morphine) [5]h a v e
not been subjected to rigorous study. While hypotension and
decreased cardiac output with neurohormonal activation
have been the traditional explanations for worsening renal
function in this setting, recent evidence has implicated high
venous pressure and raised intra-abdominal pressure leading
to renal venous congestion as important contributors to
impairment of kidney function [6, 7], and indeed many
patients with ADHF and type 1 CRS have preserved left ven-
tricular ejection fraction and normal or high blood pressure.
Hence, strategies to reduce congestion with diuretics and
possibly ultraﬁltration, and the use of vasodilators in select
patients, are important steps in early management.
The goal of diuretic use should be to deplete the
extracellular ﬂuid volume at a rate that allows adequate
time for intravascular reﬁlling from the interstitium. To
achieve adequate diuresis, infusions of loop diuretics have
been demonstrated to have greater eﬃcacy than intermittent
dosing [8], and certainly loop diuretics are preferred to
thiazides, whose actions are diminished in patients with
impaired kidney function [9]. In a recent study, ADHF
patients who developed hemoconcentration during diuresis
(presumedtobediuresedinexcessofreﬁllingrate)didinfact
have a greater risk of worsening renal function with an odds
ratio of 5.3 (P<. 001), however they also had lower 180-
day mortality, with a hazard ratio of 0.31 (P = .013) [10].
Diuretics may hence need to be withheld or reduced to allow
for plasma reﬁlling. Finding the optimal balance between
relief of ADHF symptoms while maintaining adequate
kidney function will require further study, and the optimal
dose and route of loop diuretic is being studied in the
randomized trial DOSE-AHF [11].
If kidney function continues to worsen, blockade of
the renin-angiotensin-aldosterone-system (RAAS) may be a
contributing factor, necessitating withholding or delaying
the introduction of angiotensin converting enzyme (ACE)
inhibitors or angiotensin receptor blockers (ARBs) in order
to maintain the GFR [12]. As a nonpharmacological strategy
to more vigorously manage hypervolemia and circula-
tory congestion, ultraﬁltration was demonstrated in the
UNLOAD study to be superior to diuretics, in terms of
greater weight loss, less requirement for vasoactive drugs,
andfewerrehospitalizationsandemergencyroomvisits,with
no diﬀerence in mortality [13]. The CARRESS-HF trial is
currently being undertaken to further deﬁne the use of this
therapy in patients with type 1 CRS [11].
For type 1 CRS patients with preserved or elevated
blood pressure, vasodilators such as nitroglycerin and nitro-
prusside are often used to relieve symptoms and improve
hemodynamics [14], though their eﬃcacy has not been
studied through randomized controlled trials, and their
eﬀect on reversing or preventing type 1 CRS is unknown.
The use of nitroprusside in patients with impaired kidney
function is potentially hazardous due to the accumulation of
thiocyanate [15], however, in a nonrandomized trial which
included patients with varying degrees of kidney function,
its use was associated with improved outcomes and stable
kidney function [16].
Nesiritide, a recombinant form of human B-type natri-
uretic peptide, quickly relieves dyspnea in acute heart
failure states, through a combination of decreased preload,
afterload and pulmonary vascular resistance, and increased
cardiac output. It also causes a brisk diuresis due to direct
renal eﬀects including aﬀerent arteriolar vasodilation and
decreased sodium reabsorption [17]. However, a meta-
analysis of trials in patients with ADHF found that nesiritide
didnotaverttype1CRSandincreasedmortality[18].Ongo-
ing research will hopefully clarify its role in type 1 CRS [19].
When patients have low blood pressure and poor
renal perfusion, positive inotropes such as dobutamine or
phosphodiesterase inhibitors may be required [5]. However,
the use of inotropes may actually accelerate some harmful
processes such as ischemia or arrhythmia. Milrinone, for
instance, was demonstrated to have a higher incidence of
hypotension, more arrhythmias, and no beneﬁt on mortality
or hospitalization in ADHF patients [20]. Levosimendan, a
phosphodiesteraseinhibitorwithcalciumsensitizingactivity,
has shown mixed results in terms of the prevention and
treatment of type 1 CRS [21, 22]. When patients with
ADHF or cardiogenic shock and type 1 CRS are resistant to
therapy, more invasive therapies such as intra-aortic balloon
pulsation, ventricular assist devices, or artiﬁcial hearts may
be required as a bridge to recovery of cardiac function or to
transplantation.
Finally, a number of classes of agents targeting some
of the vasoactive/neurohormonal eﬀector pathways in type
1 CRS, speciﬁcally endothelin, adenosine, and vasopressin,
have held promise in preclinical and early clinical trials.
However, subsequent randomized trials have failed to show a
beneﬁt of antagonism of receptors for these targets [23–26].
3. Management of Chronic Cardiorenal
Syndrome (Type 2)
Interruption of the RAAS is the primary goal in the man-
agement of type 2 CRS. However, RAAS blockade can lead
to signiﬁcant decrease in kidney function, and/or elevated
potassium. Studies of RAAS blockade in heart failure have
typically excluded CKD patients [27], but it is likely that
these agents are renoprotective even in this population.
The CONSENSUS trial, for example, included a number of
subjects whose serum creatinine increased by 30% or greater
with enalapril [28]. However, creatinine tended to stabilize
and in many instances improved over the course of the study.
Typically it is recommended that RAAS blockade may be
carefully titrated provided the serum creatinine does not
continue to rise beyond 30% and potassium is consistently
below 5.0mmol/L.
In terms of aldosterone blockade, drugs such as spirono-
lactone and eplerenone are an important adjunct to therapy
in patients with severe heart failure [29, 30]. However, the
use of these agents in patients with CKD, and particularly
in combination with other RAAS blockade, can dramatically4 International Journal of Nephrology
increase the risk of hospitalizations and mortality secondary
to hyperkalemia [31]. Excluding patients with moderate
CKD (creatinine level ≥2.5mg/dL or 220μmol/L) or hyper-
kalemia >5.0mmol/L, which were exclusion criteria in the
Randomized Aldactone Evaluation Study (RALES) [29], will
minimize potential life-threatening complications [32].
Interruption of sympathetic tone through the use of
beta-blockers is another important strategy for patients with
congestive heart failure or ischemic heart disease. In general,
these drugs should not adversely aﬀect kidney function.
Certain beta-blockers may be relatively contraindicated in
CKD because of altered pharmacokinetics, such as atenolol,
nadolol, or sotalol [33] ,a n di ti sw i s et oc o n s u l tap h a r -
macopoeia when prescribing beta-blockers to patients with
CKD. Carvedilol, a beta-blocker with α1 blocking eﬀects,
has been demonstrated to have favourable eﬀects on kidney
functioninsomeCRSpatients,hencemayhaveabeneﬁtover
older beta-blockers [34].
Both congestive heart failure and CKD are associated
with anemia, the latter of which is commonly treated with
erythropoiesis-stimulating agents. Furthermore, the action
of erythropoietin in the heart may reduce apoptosis, ﬁbrosis,
and inﬂammation [35, 36]. Hence, there has been intense
interest in using erythropoiesis-stimulating agents in heart
failure patients [37]. A small controlled trial suggested
that administration of erythropoiesis-stimulating agents in
patientswithtype2CRSandanemialedtoimprovedcardiac
function, reduction in left ventricular size, and lowering
of BNP [38]. However, more recent work did not ﬁnd
signiﬁcant improvement in a variety of important clinical
parameters [39]. Ongoing clinical trials are required to
establish if erythropoiesis-stimulating agents have a role to
play in the management of congestive heart failure and type
2 CRS. Another approach to anemia management in type 2
CRS is parenteral iron. In the FAIR-HF study, patients were
randomized to ferric carboxymaltose or placebo, and the
activetreatmentgroupexperiencedanimprovementinheart
failure symptoms, Patient Global Assessment, 6-minute walk
test and quality of life [40]. They also experienced a higher
GFR at the study conclusion of 3.8mL/min/1.73m2.
4. Management of Acute Reno-Cardiac
Syndrome (Type 3)
In type 3 CRS, acute kidney injury occurs as a primary
event (e.g., acute glomerulonephritis) or secondary event
(e.g., radiocontrast, exogenous or endogenous nephrotoxins,
postsurgical, etc.), and cardiac dysfunction is a common
and often times fatal sequela [41]. A common example of
type 3 CRS occurring in the hospital setting is contrast
nephropathy, particularly in patients undergoing coronary
and other angiographic procedures who have risk factors
such as preexisting CKD, diabetes, older age or volume
contraction. In these susceptible populations, prevention
may provide the best opportunity to “treat” or avoid type 3
CRS. Many potential preventive strategies have been studied,
including parenteral hydration (hypotonic or isotonic saline
or bicarbonate), diuretics, mannitol, natriuretic peptides,
dopamine, fenoldopam, theophylline, and N-acetylcysteine
[42, 43]. To date, isotonic ﬂuids have been the most suc-
cessful intervention, with some controversy surrounding the
eﬀectiveness of N-acetylcysteine. Using a sensitive deﬁnition
of acute kidney injury, Solomon and colleagues identiﬁed
a possible role for the low-osmolar, nonionic monomer
iopamidol in the prevention of contrast nephropathy [44].
In addition, they identiﬁed that the research subjects who
experiencedacutekidneyinjurywerealmosttwiceaslikelyto
have major cardiovascular events (death, stroke, myocardial
infarction, or dialysis) during the follow-up period, indica-
tive of the seriousness of type 3 CRS.
Treatment of primary kidney diseases such as acute
glomerulonephritis or kidney allograft rejection may poten-
tially lessen the risk of type 3 CRS, but this has not been
systematically studied. Furthermore, many immunosuppres-
sive drugs used for such treatment have adverse eﬀects on
the cardiovascular system through their eﬀects on blood
pressure, lipids, and glucose metabolism. For instance, a
recent meta-analysis comparing the calcineurin-inhibitors
cyclosporine and tacrolimus found greater dyslipidemia in
the cyclosporine group and higher risk of new onset diabetes
in the tacrolimus group [45]. The drug sirolimus, working
through the mammalian target of rapamycin (mTOR)
pathway, leads to even greater perturbations in lipids and
higher requirement for lipid-lowering therapy [46]. While
direct and indirect inﬂuences of these agents may be
potentially harmful to the heart, some investigators have
implicated calcineurin in the development of left ventricular
hypertrophy and heart failure in animal models [47]. The
role of immunosuppression in the prevention or conversely
the development of type 3 CRS needs further study.
5. Management of Chronic Reno-Cardiac
Syndrome (Type 4)
The management of type 4 CRS is a multifaceted approach
focusing on the reduction of cardiovascular risk factors and
complications common to CKD patients. These include, but
are not limited to, anemia, hypertension, altered bone, and
mineral metabolism, dyslipidemia, smoking, albuminuria
and malnutrition [48, 49]. Several therapies targeting such
uremic complications as anemia, homocysteine, calcium-
phosphate product and hyperparathyroidism are supported
by observational studies demonstrating the association
between adverse cardiovascular events and these conditions.
In observational studies, the treatment of anemia seems
to lessen cardiovascular events, however this has not been
borne out in randomized trials where higher hemoglobin
targets have been associated with worse outcomes [50–
53]. Hence, the use of erythropoiesis-stimulating agents to
prevent type 4 CRS seems to be ineﬀective.
Elevated homocysteine has been associated with worsen-




with diabetes and more moderate CKD [57].
Observational studies have implicated elevated calcium-
phosphateproduct,elevatedphosphate,elevatedparathyroidInternational Journal of Nephrology 5
hormone, and inadequate vitamin D receptor activation as
potential risk factors for type 4 CRS [58–60]. Clinical trials
to date have been generally disappointing. A meta-analysis
of trials studying the use of the phosphate binder sevelamer
indicated no signiﬁcant beneﬁt of therapy [61]. However, a
subgroup analysis in older patients at higher cardiovascular
risk suggests that phosphate binding may improve outcomes
[62] and intensive lowering of calcium-phosphate product
improves levels of C-reactive protein [63]. With respect
to parathyroid hormone, high levels have been associated
with adverse cardiovascular outcomes in CKD [59], and
a systematic review revealed that cinacalcet, a drug used
to lower parathyroid hormone, decreased hospitalizations
related to cardiovascular disease [64]. A large randomized
trialofcinacalcetisexamininghardcardiovascularendpoints
and mortality [65], and trials of phosphate binders and
vitamin D analogs are ongoing.
The use of “statins” (3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitors) is a cornerstone of risk factor
modiﬁcation in patients at risk for cardiac disease. Unfor-
tunately, two high-proﬁle negative trials in dialysis patients
[66, 67] have cast a shadow of doubt over the use of statins
to prevent type 4 CRS, at least in advanced CKD patients.
The recently published Study of Heart and Renal Protection
(SHARP) included 3,023 dialysis patients and 6,247 CKD
patients not on dialysis, and preliminary results showed that
a combination of simvastatin and ezetimibe lowered the risk
of major atherosclerotic events, with a risk ratio of 0.83
(0.74–0.94, P = .0022) [68]. Of interest, the subgroup of
patients on dialysis seemed to experience less of a beneﬁt
from the drug therapy, and all-cause mortality was unaf-
fected. The full publication is eagerly awaited. In an earlier
meta-analysis [69] Strippoli et al. demonstrated signiﬁcant
reductions in cardiovascular end points in CKD patients
treated with statins, though again all-cause mortality was
unchanged. Statins did not, however, cause adverse events in
subjects with CKD compared to those with normal kidney
function, and the SHARP study indicated that the combina-
tion of simvastatin and ezetimibe in this population was well
tolerated with no hepatoxic or myopathic complications.
6. Management of Secondary Cardiorenal
Syndrome (Type 5)
Examples of type 5 CRS include a heterogeneous group
of disorders, such as sepsis, systemic lupus erythematosus,
amyloidosis, and diabetes mellitus [70]. It is diﬃcult to
formulate a treatment strategy to encompass all of these
disorders, but more important is the recognition that injury
to one organ is likely to inﬂuence or injure the other organ,
and vice versa. Therapies directed to the improvement in
function of one organ need to consider the interaction with,
and role of, the other.
As sepsis is one of the more common acute disorders that
involves multiple organs, and often causes codysfunction of
kidneys and heart, it provides a suitable example for the
discussion of type 5 CRS and its management. The study of
early goal-directed therapy by Rivers et al. demonstrated that
early intervention signiﬁcantly decreased in-hospital death
due to cardiovascular collapse by approximately half (21.0
versus 10.3%; P = .02), and another study of protocol-
driven targets in patients with septic shock [71] showed
a signiﬁcant reduction in the incidence of acute renal
failure from 55.2% to 38.9% (P = .015). De Backer and
colleagues compared dopamine with norepinephrine in the
management of shock (the majority with septic shock) and
found that the dopamine group had a higher incidence of
cardiac arrhythmia, while displaying a trend towards greater
dependence on renal replacement therapy [72]. Additionally,
an important randomized study of conservative versus
liberal ﬂuid resuscitation in patients with acute lung injury
[73] found that the more conservative strategy improved
not only outcomes related to lung injury itself, such as
oxygenation and ventilator days, but this strategy also led
to less cardiovascular failure and a trend towards improved
renal outcomes. Intriguingly, animal studies indicate that in
spiteofincreasedcoronaryandrenalbloodﬂow,theseorgans
demonstrate diminished function in sepsis [74]. Another
study indicated that low-dose vasopressin was eﬀective in
limitingcardiacandkidneyinjuryinsepsis[75].Recognition
of type 5 CRS as an entity in sepsis and other systemic
disorders will allow further research into the signalling and
mechanisms of injury and allow for the development of
rational and eﬀective therapies.
7. Conclusions
The subtypes of CRS discussed in this paper present unique
management challenges, but also opportunities for further
research. Sadly, many pivotal heart failure trials of the past
decades which have been instrumental in guiding therapy for
millions of patients worldwide have systematically excluded
patients with acute or chronic kidney disease, making it
diﬃcult to provide evidence-based treatment guidelines for
type 1 and 2 CRS. The recognition of acute kidney injury as
an important clinical outcome, coupled with more stringent
and standardized diagnostic criteria, has led to a tremendous
increase in research activity in recent years. The increased
understanding of downstream consequences of acute kidney
injury, and in particular its role in type 3 CRS, has
only recently been appreciated. Clearly more high-quality
research in this area is necessary. Finally, an astonishing
number of cardioprotective trials in type 4 CRS have been
negative[76].ThisunderscorestheneedtorecognizeCKDas
afactorthatnotonlyheightensriskofcardiovasculardisease,
but also modiﬁes (or even negates) the eﬀect of treatments
proven eﬀective in other populations. Understanding the
complex bidirectional interactions between the heart and the
kidneys can only help foster future drug development and
investigations into the prevention and management of all
subtypes of CRS.
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